Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boostingSOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) —
byBenzinga Newsdesk
April 25, 2024
2 minute read
Total
0
Shares
0
0
0
0
0
0

Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (NASDAQ:ALGS, “Aligos”))))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced an ePoster flash session presentation at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2024, being held April 27-30, 2024 in Barcelona, Spain.

The presentation highlights ALG-097558 Phase 1 data showing that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect.

“We are pleased to present these ALG-097558 data, which further highlight the best-in-class potential of this pan-coronavirus protease inhibitor and its substantial differentiation versus current standard of care coronavirus antiviral drugs like nirmatrelvir/ritonavir (PAXLOVIDTM),” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “These data further demonstrate that Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates. We look forward to continuing to advance ALG-097558 for current and potential future pandemics with the financial support of various external funding sources, including government agencies.”

Details of the presentation are as follows:

  • ePoster Flash Session Presentation Title: Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers
    • Presented by Denisa Wilkes, MD, MSc, CPM, Medical Director, Hammersmith Medicines Research
    • April 28, 2024 at 8:30am CEST

       

The presentation will be available on the Scientific Presentations & Conferences section of the Aligos website (www.aligos.com) after the live event.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

New York Kicks Off 2024 With New Legal Weed Shops, Other Stores Open In OH, PA And FLA

By Jelena Martinovic
January 16, 9:52 AM
New York is starting off 2024 with the opening of several cannabis shops, demonstrating the growth and diversification of the state's industry. The Flowery on Staten Island is set to open on 17 January and will offer recreational cannabis in collaboration with local cultivators and brands. Meanwhile, The Herbal Care in New York City and Verona Collective in Verona have already begun selling cannabis, with both outlets exclusively featuring products from New York farmers. Orange County Cannabis in Wawayanda has also begun sales as the 45th adult-use dispensary in the state. In addition to New York, three other US states have seen new cannabis stores open. Ascend Wellness Holdings has set up its flagship store next to the Hard Rock Casino in Cincinnati, Ohio. Jushi Holdings has relocated its Beyond Hello Hazleton dispensary in Pennsylvania, while Verano Holdings has opened its 74th Florida dispensary, MÜV Yulee.

AAWH